Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.

Conditions

• Keloids

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bevacizumab — DRUG
  anti-VEGF
• Triamcinolone Acetonide — DRUG
  corticosteroid

Study Details

The study compares the efficacy and safety of intralesional bevacizumab versus corticosteroids for the treatment of keloids. Assessment will be done clinically by the use of Modified Vancouver Scar Scale. Erythema index will be measured by spectrophotometry. The levels of Vascular Endothelial Growth Factor, collagen type 1 and collagen type 3 in the lesions before and after each treatment modality.

Key Dates

First listed

Jun 10, 2025

Start date

Sep 1, 2023

Status verified

Jun 2025

Primary completion

Sep 1, 2024

Completion

Jul 1, 2025

Study Design

Enrollment

28 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Intralesional bevacizumab injection
  Intralesional bevacizumab injection for the treatment of keloid
• Active Comparator: Intralesional corticosteroid injection
  Intralesional triamcinolone acetonide injection for the treatment of keloids

Primary Outcome Measure

Modified Vancouver scar scale (mVSS) [ Time Frame: 6 months ]